Search
Piper Sandler Senior Analyst David Amsellem reacts to today's Teva Innovation & Strategy Day and shares his take on the company's pipeline
He gives his thoughts on the competitiveness of Teva's TL1A, and highlights other pipeline programs that biotech investors might look at....
May 29, 2025
At Teva's Innovation & Strategy Day in New York today, CEO Richard Francis discusses what 'Pivot to Growth' means for the company and offers takeaways from the presentation
He highlights Teva's improved financial position, its commercial prowess, and the pipeline assets to watch, including a TL1A that biotech...
May 29, 2025
Previewing top breast cancer and antibody-drug conjugate presentations to watch at this week's ASCO Annual Meeting with Dana-Farber's Paolo Tarantino
He describes key presentations for Enhertu, TRODELVY, immunotherapy medicines, and a couple key biomarkers to watch.
May 28, 2025
RBC Global Healthcare Conference: Desk Strategist Chris McCarthy shares how institutional investors have been affected by policy and macro factors, and how they have been positioning around catalysts
He describes how policy, macro, and events have been affecting trading in biotech stocks lately. Plus, his thoughts on the pull back of...
May 21, 2025
RBC Global Healthcare Conference: Senior Biotech Analyst Luca Issi shares his thoughts on the current state of gene and cell therapy
He shares his overall thoughts on the biotech market, and discusses gene therapies, RNA editing, and cell therapy. Luca Issi RBC 2025
May 21, 2025
RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year
CEO Ram Aiyar describes Korro's 'OPERA' platform and explains why he thinks it is differentiated from others in the field. He previews...
May 21, 2025
RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead
CEO Sanjay Shukla describes the science behind tRNA synthetase biology and how aTyr is leveraging it against inflammatory and fibrotic...
May 21, 2025
RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD
He describes where he sees AXPAXLI fitting into the treatment paradigm, and shares an update on the SOL-1 and SOL-R studies - including...
May 21, 2025
RBC Global Healthcare Conference: RBC's Brian Abrahams shares his take on biotech and offers advice for companies on how to navigate these times of change
He describes some of the discussions he is having at the conference, discusses the difference between how large companies he covers are...
May 21, 2025
RBC Global Healthcare Conference: Ahead of an important trial readout next month, Jeff Stein explains Cidara's unique approach to influenza and how it differs from vaccines
He describes the science behind Cidara's Cloudbreak Drug-Fc conjugates, which might have uniform efficacy regardless of how the flu...
May 21, 2025
Stevenage, UK based TessellateBio recently signed a collaboration and licensing deal with Boehringer Ingelheim targeting tumors dependent on alternative lengthening of telomeres (ALT) for their growth
CEO Andree Blaukat describes TessellateBio's focus on synthetic lethality and the science behind this lead area they have partnered with...
May 20, 2025
GENESIS Pharma is bringing global innovation closer to patients in Central and Eastern Europe
Already a partner for many of the world's top biopharma companies in this important region, see how GENESIS Pharma can help your company...
May 20, 2025
BioVenture VoiCes Episode 19: Longwood Fund's Christoph Westphal
Dr. Westphal describes his upbringing and early career at McKinsey and Polaris, founding or co-founding companies like Momenta, Alnylam,...
May 19, 2025
Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs
CEO Arndt Schottelius describes the rationale behind the KnotBody platform and the company's future plans to develop them against things...
May 16, 2025
Meet NewBiologix, an innovative Swiss biotech company dedicated to revolutionizing the field of gene therapy
At #ASGCT2025, we met up with Founder and CEO Igor Fisch, who described the pillars that make NewBiologix a partner of choice in the rAAV...
May 16, 2025
ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk
CEO Alvin Luk and CTO TJ Cradick explain how the company's Cas12 and 13 programs are different than Cas9, and they discuss the DMD...
May 15, 2025
ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions
He talks about new capsids Dyno announced at this years' conference and the science behind getting them to specific places in the body....
May 15, 2025
ASGCT 2025: Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account, and what this means for drug development
As published in NEJM today , UPenn's Kiran Musunuru describes how the team used base editing in a matter of months to treat an infant...
May 15, 2025
ASGCT 2025: Coave Therapeutics presented a late breaker showing a positive profile for its cerebrospinal fluid administered ligand-engineered AAV2-based capsid
CEO Rodolphe Clerval walks us through Coave's "ALIGATER' ligand technology and describes the importance of the cerebrospinal administered...
May 15, 2025
Cambridge, UK based Alchemab Therapeutics last week signed a second collaboration with Eli Lilly worth up to $415M to license its IND ready program for ALS and other neurodegenerative diseases
CEO Jane Osbourn describes Alchemab's platform, which looks for people who are resilient to disease and then sequences them to understand...
May 15, 2025
.png){kind=logo}
